Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting clinical trials

Explore recruiting pre and post menopausal women with hr her2 labc or mbc whose disease has progressed to cdk4 6 inhibitor in combination with a hormonal therapy in the adjuvant or metastatic setting clinical trials.

Also recruiting in Europe

Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting trials by city

Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Toronto Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Vancouver Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Montreal Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Calgary Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Edmonton Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Ottawa Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Winnipeg Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Quebec City Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Hamilton Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Kitchener Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in London Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Halifax Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in New York Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Los Angeles Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Chicago Pre And Post Menopausal Women With Hr Her2 Labc Or Mbc Whose Disease Has Progressed To Cdk4 6 Inhibitor In Combination With A Hormonal Therapy In The Adjuvant Or Metastatic Setting in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease